Showing results (11-20 of 40) with videos related to
Sort By:
Pageof 4
Biomedicines|July 28, 2026
Navigating the Therapeutic Landscape of Multiple Myeloma: Immunotherapy, Microenvironment, and ResistanceSreejeta Mondal, Nathan Becker, Yang Huo, et al.JAMA|February 1, 2022
Diagnosis and Management of Multiple Myeloma: A ReviewAndrew J Cowan, Damian J Green, Mary Kwok, et al.Blood Advances|July 1, 2025
Tocilizumab Prophylaxis for Patients with Multiple Myeloma Treated with Bispecific AntibodiesAndrew Kowalski, Jillian Lykon, Benjamin T Diamond, et al.Cancer Research|March 5, 2008
MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell linesLynne T Bemis, Robert Chen, Carol M Amato, et al.Transplantation and Cellular Therapy|April 25, 2021
Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective AnalysisAndrew J Cowan, Philip A Stevenson, Damian J Green, et al.Clinical Lymphoma, Myeloma & Leukemia|May 28, 2020
KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell TransplantationAndrew J Cowan, Damian J Green, Mehdi Karami, et al.Journal for Immunotherapy of Cancer|April 12, 2024
Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myelomaDavid G Coffey, Keren Osman, Adolfo Aleman, et al.Blood|October 7, 2024
Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapyDavid G Coffey, Pinar Ataca Atilla, Erden Atilla, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 27, 2018
Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance TherapyAndrew J Cowan, Philip A Stevenson, Edward N Libby, et al.Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|November 24, 2016
Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantationAndrew J Cowan, Zandra K Klippel, Philip A Stevenson, et al.Pageof 4